Trusted Resource for Clinical Trials, Protocols & Progress
Sponsors should partner early with advocacy groups, establish collaborations with Tier-1 hospitals, and explore decentralized trial models for broader patient access. Regulatory engagement is critical to clarify expectations for trial design, patient numbers, and data acceptance. Building registries and integrating RWE strengthens submissions and accelerates approval.
Click to read the full article.
Sponsors should design protocols that account for pediatric-specific needs, such as child-friendly formulations, age-appropriate consent, and long-term follow-up. Early engagement with the NMPA and ethics committees ensures smoother approvals. Collaborations with pediatric hospitals and CROs improve recruitment and compliance with GCP standards.
Click to read the full article.
Sponsors should select NMPA-accredited sites with strong track records, validate bioanalytical methods, and ensure SOP compliance. Early regulatory engagement clarifies comparator selection and study design expectations. CRO partnerships enhance operational quality, while mock inspections prepare sites for NMPA audits.
Click to read the full article.
Sponsors should establish site-level QA frameworks that include SOPs, routine audits, and inspection readiness programs. Training site staff in GCP and QA principles is critical. Engaging CROs for QA support, implementing electronic systems, and harmonizing SOPs across global sites reduce risks and improve efficiency.
Click to read the full article.
Sponsors should:
✔️ Standardize herbal formulations through Good Manufacturing Practice (GMP)
✔️ Use randomized, placebo-controlled designs where feasible
✔️ Develop composite endpoints that reflect both TCM and Western outcomes
✔️ Train investigators in integrative trial methodologies
✔️ Collaborate with CROs and TCM research networks for operational support
These practices improve the scientific credibility of TCM trials and enhance regulatory acceptance.
Click to read the full article.
Sponsors should plan China-inclusive trials early in global development. Best practices include:
✔️ Aligning protocols with ICH E17 and NMPA requirements
✔️ Engaging CROs with strong China operations
✔️ Expanding site networks beyond Tier-1 hospitals
✔️ Addressing data localization through local IT infrastructure
✔️ Training investigators in global GCP standards
✔️ Proactive regulatory engagement with the NMPA and ethics committees
These practices mitigate risks and ensure smooth integration of China into global programs.
Click to read the full article.
Sponsors should:
✔️ Secure trial-specific liability insurance early in planning
✔️ Ensure coverage includes medical costs, disability, and death compensation
✔️ Provide transparent insurance documentation to ethics committees
✔️ Negotiate clear indemnification clauses with sites
✔️ Engage CROs to manage local insurance procurement and compliance
These measures reduce approval delays and protect participant rights.
Click to read the full article.
Sponsors should:
✔️ Incorporate pharmacoeconomic endpoints early in trial design
✔️ Engage with the NHSA to understand NRDL priorities
✔️ Use RWE to complement clinical data
✔️ Align trial sites with regions prioritized for reimbursement access
✔️ Partner with CROs experienced in pharmacoeconomic data collection
These best practices increase the chances of NRDL inclusion and accelerate patient access.
Click to read the full article.
Sponsors should:
✔️ Validate AI tools through pilot studies before large-scale use
✔️ Ensure compliance with NMPA and PIPL requirements
✔️ Partner with local hospitals and CROs with digital expertise
✔️ Invest in interoperable data platforms for multi-site trials
✔️ Maintain human oversight in AI-driven processes
These practices help sponsors maximize benefits while ensuring compliance and ethics.
Click to read the full article.
Sponsors should:
✔️ Identify candidates early for fast-track pathways
✔️ Engage the NMPA proactively through consultations
✔️ Design trials incorporating surrogate endpoints where relevant
✔️ Plan robust post-market studies for Conditional Approval
✔️ Coordinate with CROs to manage expedited timelines and inspections
Strategic use of these pathways accelerates approvals while ensuring compliance.
Click to read the full article.
